Schöttle, JakobChatterjee, SampurnaVolz, CarolineSiobal, MaikeFlorin, AlexandraRokitta, DennisHinze, YvonneDietlein, FelixPlenker, DennisKönig, KatharinaAlbus, KerstinHeuckmann, Johannes M.Rauh, DanielFranz, ThomasNeumaier, BerndFuhr, UweHeukamp, Lukas C.Ullrich, Roland T.2016-04-012015Schöttle, J., S. Chatterjee, C. Volz, M. Siobal, A. Florin, D. Rokitta, Y. Hinze, et al. 2015. “Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.” Oncotarget 6 (36): 38458-38468.1949-2553http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318541Treatment with EGFR kinase inhibitors improves progression-free survival of patients with EGFR-mutant lung cancer. However, all patients with initial response will eventually acquire resistance and die from tumor recurrence. We found that intermittent high-dose treatment with erlotinib induced apoptosis more potently and improved tumor shrinkage significantly than the established low doses. In mice carrying EGFR-mutant xenografts intermittent high-dose treatment (200 mg/kg every other day) was tolerable and prolonged progression-free survival and reduced the frequency of acquired resistance. Intermittent EGFR-targeted high-dose schedules induce more profound as well as sustained target inhibition and may afford enhanced therapeutic efficacy.en-USlung cancerNSCLCEGFRerlotinibhigh-dose schedulingPETJournal Article2016-04-0110.18632/oncotarget.6276